[go: up one dir, main page]

US20050020662A1 - Inhibition of PKC to treat permability failure - Google Patents

Inhibition of PKC to treat permability failure Download PDF

Info

Publication number
US20050020662A1
US20050020662A1 US10/863,114 US86311404A US2005020662A1 US 20050020662 A1 US20050020662 A1 US 20050020662A1 US 86311404 A US86311404 A US 86311404A US 2005020662 A1 US2005020662 A1 US 2005020662A1
Authority
US
United States
Prior art keywords
inhibitor
pkc
dialysis fluid
peritoneal dialysis
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/863,114
Inventor
George King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joslin Diabetes Center Inc
Original Assignee
Joslin Diabetes Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc filed Critical Joslin Diabetes Center Inc
Priority to US10/863,114 priority Critical patent/US20050020662A1/en
Publication of US20050020662A1 publication Critical patent/US20050020662A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Definitions

  • the invention relates to peritoneal dialysis fluids, and methods of making and using them. More particularly, it relates to the methods for preventing and treating complications due to peritoneal dialysis.
  • Peritoneal dialysis can be used to treat patients having chronic renal failure.
  • peritoneal dialysis fluid is introduced into the peritoneal cavity of a subject.
  • the fluid generally has a high glucose level, often in the 100 mM range.
  • Introduction of this relatively high molarity fluid into the peritoneum causes the osmotic extraction of toxins, for example, urea creatinine, and other substances normally removed by the kidney, from the blood. It can also reduce the level of fluid in the patient.
  • the invention is based, in part, on the discovery that the use of peritoneal dialysis fluid, especially prolonged use, can result in decreasing permeability between the peritoneal dialysis fluid and the blood compartment, that high levels of glucose are involved in changes in the cells lining the peritoneum, that the high glucose levels activate PKC, and that the inhibition of PKC can prevent this chronic complication.
  • the invention can treat an undesirable decrease in the efficiency of exchange between the peritoneal dialysis fluid and the vascular compartment.
  • the invention features, a method of treating a subject.
  • the method includes:
  • an inhibitor of PKC is included in the peritoneal dialysis fluid.
  • the inhibitor is preferably a specific inhibitor of PKC.
  • the inhibitor can be an inhibitor of a PKC ⁇ , e.g., ⁇ 1 or ⁇ 2, ⁇ , ⁇ , or other isoform.
  • the inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC ⁇ inhibitor LY333531, which is described in Ishi et al. (1996) Science 272:728-731, hereby incorporated by reference.
  • LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nanometers.
  • the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • Peritoneal dialysis fluid of the invention is particularly useful for subjects who are already peritoneal dialysis patients.
  • the subject has been a peritoneal dialysis patient for at least 2, 4, 6, 12, or 24 months, e.g., the subject has been administered peritoneal dialysis fluid, either one with or without a PKC inhibitor, periodically for at least 2, 4, 6, 12, or 24 months, or it has been at least 2, 4, 6, 12, or 24 months since the subjects first peritoneal dialysis administration.
  • Peritoneal dialysis fluid of the invention can be administered to patients who have already developed permeability disjunction.
  • peritoneal dialysis fluid of the invention is useful for subjects who have not yet had peritoneal dialysis.
  • Peritoneal dialysis fluid of the invention can be administered to patients who have not yet developed permeability disjunction.
  • the invention features, a method of treating a subject.
  • the method includes:
  • peritoneal dialysis fluid and an inhibitor of a PKC into the subject, thereby treating the subject.
  • the peritoneal dialysis fluid and PKC inhibitor are co-administered to the subject; the peritoneal dialysis fluid and PKC inhibitor are introduced separately into the subject; the peritoneal dialysis fluid and PKC inhibitor are combined prior to introduction into the subject and administered together.
  • an inhibitor of PKC is included in the peritoneal dialysis fluid.
  • the inhibitor is preferably a specific inhibitor of PKC.
  • the inhibitor can be an inhibitor of a PKC ⁇ , e.g., ⁇ 1 or ⁇ 2, ⁇ , ⁇ , or other isoform, or combinations thereof.
  • the inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC ⁇ inhibitor LY333531.
  • LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nanometers.
  • the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • the subject is administered a second, third, fourth, or fifth, infusion of peritoneal dialysis fluid.
  • Peritoneal dialysis fluid of the invention is particularly useful for subjects who are already peritoneal dialysis patients.
  • the subject has been a peritoneal dialysis patient for at least 2, 4, 6, 12, or 24 months, e.g., the subject has been administered peritoneal dialysis fluid, either one with or without a PKC inhibitor, periodically for at least 2, 4, 6, 12, or 24 months, or it has been at least 2, 4, 6, 12, or 24 months since the subjects first peritoneal dialysis administration.
  • Peritoneal dialysis fluid of the invention can be administered to patients which have already developed permeability disjunction.
  • peritoneal dialysis fluid of the invention is useful for subjects who have not yet had peritoneal dialysis.
  • Peritoneal dialysis fluid of the invention can be administered to patients which have not yet developed permeability disjunction.
  • the subject is at risk for renal failure, for example, the subject is a patient in end-stage renal failure.
  • the invention features, a peritoneal dialysis fluid which includes an inhibitor of a PKC.
  • the peritoneal dialysis fluid is one described herein.
  • an inhibitor of PKC is included in the peritoneal dialysis fluid.
  • the inhibitor is preferably a specific inhibitor of PKC.
  • the inhibitor can be an inhibitor of a PKC ⁇ , e.g., ⁇ 1 or ⁇ 2, ⁇ , ⁇ , or other isoform, or combinations thereof.
  • the inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC ⁇ inhibitor LY333531.
  • LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nM.
  • the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • the invention features, a method of making an improved peritoneal dialysis fluid.
  • the method includes, providing a peritoneal dialysis fluid and adding to that fluid an inhibitor of a PKC, for example an inhibitor described herein, for example LY333531.
  • an inhibitor of PKC is included in the peritoneal dialysis fluid.
  • the inhibitor is preferably a specific inhibitor of PKC.
  • the inhibitor can be an inhibitor of a PKC ⁇ , e.g., ⁇ 1 or ⁇ 2, ⁇ , ⁇ , or other isoform, or combinations thereof.
  • the inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC ⁇ inhibitor LY333531.
  • LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nM.
  • the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • Subject can refer to a human subject, or a non-human animal, for example, a horse, cow, goat, pig, sheep or other veterinary, food or fiber producing animal, in need of dialysis.
  • the subject can be an individual at risk for (e.g., the individual can have or be predisposed to have) end-stage renal disease, from any cause.
  • FIG. 1 shows PKC activity of primary human mesothelial cells at various glucose levels (i.e., low glucose, 60 mM or 150 mM glucose). The PKC activity was determined in the presence or absence or PMA, an activator of PKC.
  • FIG. 2 shows the effect of treatment with vitamin E on PKC activity of human primary mesothelial cells.
  • the mesothelial cells were exposed to low or high (150 mM) levels of glucose in the presence or absence of PMA, an activator of PKC, and the presence or absence of vitamin E, a PKC inhibitor.
  • FIG. 3 shows PKC activity of primary human mesothelial cells cultured in low glucose concentrations, high glucose concentrations (i.e., 60 mM or 150 mM), or mannitol.
  • the PKC activity was determined in the presence or absence or PMA, an activator of PKC.
  • FIG. 4 shows DAG activity of transformed mesothelial cells at low glucose levels (5.5 mM) and high glucose levels (60 mM).
  • Peritoneal dialysis for chronic renal failure is used by some patients with renal failure.
  • the fluid for peritoneal dialysis uses glucose at 400-mM range. While not wishing to be bound by theory, it appears that at this concentration level, glucose causes complications which can lead to decreasing permeability between the peritoneal dialysis fluid and the blood compartment. The elevation of high glucose causes changes in the cells lining the peritoneum.
  • the invention is based, in part on, PKC activation, which is believed to cause this chronic decrease in the exchange between the peritoneal fluid and a vascular compartment.
  • PKC activation induced by hyperglycemia either in the peritoneal fluid or in the blood causes cells to behave abnormally.
  • the inhibition of PKC ⁇ isoform by the inhibitor LY333531 can prevent many of the vascular changes induced by glucose levels up to 20-30 mM.
  • the higher concentration of glucose as used in peritoneal dialysis will also increase PCK activation.
  • Inhibition of PKC activation using a PKC ⁇ , e.g., ⁇ 1 or ⁇ 2, ⁇ , ⁇ , or other isoform, or combinations thereof, inhibitor will prevent the thickening and the decrease in exchange between peritoneal and vascular compartments, which will improve the efficiency of peritoneal dialysis for chronic renal failure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention features a method of treating a subject, e.g., a subject having permeability disjunction, which includes administering to the subject peritoneal dialysis fluid which includes an inhibitor of PKC, e.g., an inhibitor of PKC β. The invention also features an improved peritoneal dialysis fluid and methods of making such dialysis fluid.

Description

  • This application is a continuation of, and claims the benefit of, U.S. patent application Ser. No. 09/524,459, filed Mar. 10, 2000, which claims the benefit of Provisional Application No. 60/124,043, filed Mar. 12, 1999, the contents of which are incorporated in their entirety.
    • BACKGROUND OF THE INVENTION
  • The invention relates to peritoneal dialysis fluids, and methods of making and using them. More particularly, it relates to the methods for preventing and treating complications due to peritoneal dialysis.
  • Peritoneal dialysis can be used to treat patients having chronic renal failure. In this procedure, peritoneal dialysis fluid is introduced into the peritoneal cavity of a subject. The fluid generally has a high glucose level, often in the 100 mM range. Introduction of this relatively high molarity fluid into the peritoneum causes the osmotic extraction of toxins, for example, urea creatinine, and other substances normally removed by the kidney, from the blood. It can also reduce the level of fluid in the patient.
    • SUMMARY OF THE INVENTION
  • The invention is based, in part, on the discovery that the use of peritoneal dialysis fluid, especially prolonged use, can result in decreasing permeability between the peritoneal dialysis fluid and the blood compartment, that high levels of glucose are involved in changes in the cells lining the peritoneum, that the high glucose levels activate PKC, and that the inhibition of PKC can prevent this chronic complication. The invention can treat an undesirable decrease in the efficiency of exchange between the peritoneal dialysis fluid and the vascular compartment.
  • Accordingly, the invention features, a method of treating a subject. The method includes:
  • introducing peritoneal dialysis fluid into the peritoneum of the subject; and
  • inhibiting a PKC in the subject, thereby treating said subject.
  • In a preferred embodiment, an inhibitor of PKC is included in the peritoneal dialysis fluid. The inhibitor is preferably a specific inhibitor of PKC. The inhibitor can be an inhibitor of a PKC β, e.g., β1 or β2, γ, δ, or other isoform. The inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC β inhibitor LY333531, which is described in Ishi et al. (1996) Science 272:728-731, hereby incorporated by reference. LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nanometers.
  • In a preferred embodiment, the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • Peritoneal dialysis fluid of the invention is particularly useful for subjects who are already peritoneal dialysis patients. In preferred embodiments, the subject has been a peritoneal dialysis patient for at least 2, 4, 6, 12, or 24 months, e.g., the subject has been administered peritoneal dialysis fluid, either one with or without a PKC inhibitor, periodically for at least 2, 4, 6, 12, or 24 months, or it has been at least 2, 4, 6, 12, or 24 months since the subjects first peritoneal dialysis administration. Peritoneal dialysis fluid of the invention can be administered to patients who have already developed permeability disjunction.
  • In other embodiments peritoneal dialysis fluid of the invention is useful for subjects who have not yet had peritoneal dialysis. Peritoneal dialysis fluid of the invention can be administered to patients who have not yet developed permeability disjunction.
  • In another aspect, the invention features, a method of treating a subject. The method includes:
  • introducing peritoneal dialysis fluid and an inhibitor of a PKC into the subject, thereby treating the subject.
  • In a preferred embodiment, the peritoneal dialysis fluid and PKC inhibitor are co-administered to the subject; the peritoneal dialysis fluid and PKC inhibitor are introduced separately into the subject; the peritoneal dialysis fluid and PKC inhibitor are combined prior to introduction into the subject and administered together.
  • In a preferred embodiment, an inhibitor of PKC is included in the peritoneal dialysis fluid. The inhibitor is preferably a specific inhibitor of PKC. The inhibitor can be an inhibitor of a PKC β, e.g., β1 or β2, γ, δ, or other isoform, or combinations thereof. The inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC β inhibitor LY333531. LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nanometers.
  • In a preferred embodiment, the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • In a preferred embodiment, the subject is administered a second, third, fourth, or fifth, infusion of peritoneal dialysis fluid.
  • Peritoneal dialysis fluid of the invention is particularly useful for subjects who are already peritoneal dialysis patients. In preferred embodiments the subject has been a peritoneal dialysis patient for at least 2, 4, 6, 12, or 24 months, e.g., the subject has been administered peritoneal dialysis fluid, either one with or without a PKC inhibitor, periodically for at least 2, 4, 6, 12, or 24 months, or it has been at least 2, 4, 6, 12, or 24 months since the subjects first peritoneal dialysis administration. Peritoneal dialysis fluid of the invention can be administered to patients which have already developed permeability disjunction.
  • In other embodiments, peritoneal dialysis fluid of the invention is useful for subjects who have not yet had peritoneal dialysis. Peritoneal dialysis fluid of the invention can be administered to patients which have not yet developed permeability disjunction.
  • In a preferred embodiment, the subject is at risk for renal failure, for example, the subject is a patient in end-stage renal failure.
  • In another aspect, the invention features, a peritoneal dialysis fluid which includes an inhibitor of a PKC.
  • In a preferred embodiment, the peritoneal dialysis fluid is one described herein.
  • In a preferred embodiment, an inhibitor of PKC is included in the peritoneal dialysis fluid. The inhibitor is preferably a specific inhibitor of PKC. The inhibitor can be an inhibitor of a PKC β, e.g., β1 or β2, γ, δ, or other isoform, or combinations thereof. The inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC β inhibitor LY333531. LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nM.
  • In a preferred embodiment, the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • In yet another aspect, the invention features, a method of making an improved peritoneal dialysis fluid. The method includes, providing a peritoneal dialysis fluid and adding to that fluid an inhibitor of a PKC, for example an inhibitor described herein, for example LY333531.
  • In a preferred embodiment, an inhibitor of PKC is included in the peritoneal dialysis fluid. The inhibitor is preferably a specific inhibitor of PKC. The inhibitor can be an inhibitor of a PKC β, e.g., β1 or β2, γ, δ, or other isoform, or combinations thereof. The inhibitor can be, for example, a bis (indolyl) maleimide, for example, the PKC β inhibitor LY333531. LY333531 can be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nM.
  • In a preferred embodiment, the concentration of glucose in the peritoneal dialysis fluid is 200 nM.
  • Subject, as used herein, can refer to a human subject, or a non-human animal, for example, a horse, cow, goat, pig, sheep or other veterinary, food or fiber producing animal, in need of dialysis. The subject can be an individual at risk for (e.g., the individual can have or be predisposed to have) end-stage renal disease, from any cause.
  • Other features and advantages of the invention will be apparent from the description herein and from the claims.
    • DETAILED DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows PKC activity of primary human mesothelial cells at various glucose levels (i.e., low glucose, 60 mM or 150 mM glucose). The PKC activity was determined in the presence or absence or PMA, an activator of PKC.
  • FIG. 2 shows the effect of treatment with vitamin E on PKC activity of human primary mesothelial cells. The mesothelial cells were exposed to low or high (150 mM) levels of glucose in the presence or absence of PMA, an activator of PKC, and the presence or absence of vitamin E, a PKC inhibitor.
  • FIG. 3 shows PKC activity of primary human mesothelial cells cultured in low glucose concentrations, high glucose concentrations (i.e., 60 mM or 150 mM), or mannitol. The PKC activity was determined in the presence or absence or PMA, an activator of PKC.
  • FIG. 4 shows DAG activity of transformed mesothelial cells at low glucose levels (5.5 mM) and high glucose levels (60 mM).
    • DETAILED DESCRIPTION
  • Peritoneal dialysis for chronic renal failure is used by some patients with renal failure. The fluid for peritoneal dialysis uses glucose at 400-mM range. While not wishing to be bound by theory, it appears that at this concentration level, glucose causes complications which can lead to decreasing permeability between the peritoneal dialysis fluid and the blood compartment. The elevation of high glucose causes changes in the cells lining the peritoneum. The invention is based, in part on, PKC activation, which is believed to cause this chronic decrease in the exchange between the peritoneal fluid and a vascular compartment.
  • PKC activation induced by hyperglycemia either in the peritoneal fluid or in the blood causes cells to behave abnormally. The inhibition of PKC β isoform by the inhibitor LY333531 can prevent many of the vascular changes induced by glucose levels up to 20-30 mM. The higher concentration of glucose as used in peritoneal dialysis will also increase PCK activation. Inhibition of PKC activation using a PKC β, e.g., β1 or β2, γ, δ, or other isoform, or combinations thereof, inhibitor will prevent the thickening and the decrease in exchange between peritoneal and vascular compartments, which will improve the efficiency of peritoneal dialysis for chronic renal failure.
  • As shown in FIGS. 1-3, exposure of human mesothelial cells, which are the cells that line the peritoneum, to glucose levels of 60 mM or 150 mM results in an increase of PKC activity. These concentrations of glucose are standard for dialysis. In addition, as shown in FIG. 2, exposure of these cells to vitamin E, which is an inhibitor of PKC, resulted in a decrease of PKC activity. It was also found that high glucose levels of 60 mM or 150 mM increased DAG activity. These results demonstrate that glucose concentrations used for peritoneal dialysis activate the DAG-PKC pathways. It has been reported that activation of these pathways increases fibrosis. These results also show that inhibitors of PKC such as vitamin E decrease PKC activity. Therefore, inhibition of PKC can decrease fibrosis and reduce or prevent permeability failure of the peritoneal membrane.
  • Other embodiments are within the following claim.

Claims (24)

1. A method of treating a subject, comprising:
introducing into said subject a peritoneal dialysis fluid which includes an inhibitor of a PKC, thereby treating said subject.
2. The method of claim 1, wherein said inhibitor is a specific inhibitor of PKC.
3. The method of claim 2, wherein said inhibitor is selected from the group consisting of: an inhibitor of a PKC β, an inhibitor of PKC γ, and an inhibitor of PKC δ.
4. The method of claim 2, wherein said inhibitor is an inhibitor of PKC β.
5. The method of claim 4, wherein said inhibitor is an inhibitor of PKC β1.
6. The method of claim 4, wherein said inhibitor is a bis (indolyl) maleimide.
7. The method of claim 6, wherein said inhibitor is LY333531.
8. The method of claim 7, wherein said LY333531 is present in said dialysis fluid at about 1-1,000 nanometers.
9. The method of claim 1, wherein said dialysis fluid has a concentration of glucose of about 200 nM.
10. The method of claim 1, wherein said subject has previously received peritoneal dialysis.
11. The method of claim 1, wherein said subject has been a peritoneal dialysis patient for at least 2 to 24 months.
12. The method of claim 1, wherein said subject has already developed permeability disjunction.
13. The method of claim 1, wherein said subject has not yet developed permeability disjunction.
14. The method of claim 1, wherein said subject is at risk for renal failure.
15. The method of claim 14, wherein said subject is in end-stage renal failure.
16. A peritoneal dialysis fluid comprising an inhibitor of a PKC.
17. The dialysis fluid of claim 16, wherein said inhibitor is a specific inhibitor of PKC.
18. The dialysis fluid of claim 17, wherein said inhibitor is an inhibitor of PKC β.
19. The dialysis fluid of claim 18, wherein said inhibitor is a bis (indolyl) maleimide.
20. The dialysis fluid of claim 19, wherein said inhibitor is LY333531.
21. The dialysis fluid of claim 20, wherein said LY333531 is present in said dialysis fluid at about 1-1,000 nanometers.
22. The dialysis fluid of claim 16, wherein said dialysis fluid has a concentration of glucose of about 200 nM.
23. A method of making an improved peritoneal dialysis fluid, comprising:
providing a peritoneal dialysis fluid; and
adding to that fluid an inhibitor of a PKC, to thereby provide an improved dialysis fluid.
24. The method of claim 23, wherein said inhibitor is LY333531.
US10/863,114 1999-03-12 2004-06-07 Inhibition of PKC to treat permability failure Abandoned US20050020662A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/863,114 US20050020662A1 (en) 1999-03-12 2004-06-07 Inhibition of PKC to treat permability failure

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12404399P 1999-03-12 1999-03-12
US09/524,459 US6753341B1 (en) 1999-03-12 2000-03-10 Inhibition of PKC to treat permability failure
US10/863,114 US20050020662A1 (en) 1999-03-12 2004-06-07 Inhibition of PKC to treat permability failure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/524,459 Continuation US6753341B1 (en) 1999-03-12 2000-03-10 Inhibition of PKC to treat permability failure

Publications (1)

Publication Number Publication Date
US20050020662A1 true US20050020662A1 (en) 2005-01-27

Family

ID=32473968

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/524,459 Expired - Fee Related US6753341B1 (en) 1999-03-12 2000-03-10 Inhibition of PKC to treat permability failure
US10/863,114 Abandoned US20050020662A1 (en) 1999-03-12 2004-06-07 Inhibition of PKC to treat permability failure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/524,459 Expired - Fee Related US6753341B1 (en) 1999-03-12 2000-03-10 Inhibition of PKC to treat permability failure

Country Status (1)

Country Link
US (2) US6753341B1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9144594B2 (en) * 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
US7966263B2 (en) * 2006-05-04 2011-06-21 First Data Corporation Wireless phone RF presentation instrument with sensor control
US9466057B2 (en) * 2006-05-04 2016-10-11 First Data Corporation RF presentation instrument with sensor control
US7991692B2 (en) * 2006-10-09 2011-08-02 First Data Corporation Electronic payment instrument and packaging
US8157178B2 (en) 2007-10-19 2012-04-17 First Data Corporation Manufacturing system to produce contactless devices with switches
US7885878B2 (en) * 2008-05-28 2011-02-08 First Data Corporation Systems and methods of payment account activation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736564A (en) * 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US20010011076A1 (en) * 1996-02-20 2001-08-02 Gary K. Schwartz Combinations of pkc inhibitors and therapeutic agents for treating cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736564A (en) * 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
US20010011076A1 (en) * 1996-02-20 2001-08-02 Gary K. Schwartz Combinations of pkc inhibitors and therapeutic agents for treating cancers
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists

Also Published As

Publication number Publication date
US6753341B1 (en) 2004-06-22

Similar Documents

Publication Publication Date Title
Maiorca et al. CAPD viability: a long-term comparison with hemodialysis
JP5690040B2 (en) Bicarbonate-based peritoneal dialysis solution
US20060128658A1 (en) Biocompatible dialysis fluids containing icodextrins
DE69332433T2 (en) IMPROVED AMINO ACID SOLUTIONS FOR PERITONEAL DIALYSIS TREATMENT
JP2009131669A (en) Bicarbonate-based solution in single container
Palmer Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose
Mariat et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation
Fischer et al. Veterinary hemodialysis: advances in management and technology
Nascimento et al. On the mechanism of lithium-induced renal tubular acidosis
Bailey et al. Comparison of intermittent haemodialysis, prolonged intermittent renal replacement therapy and continuous renal replacement haemofiltration for lithium toxicity: a case report
Yong et al. Rituximab and omalizumab in severe, refractory insulin allergy
Peers et al. Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume
Kim et al. Continuous renal replacement therapy does not have a clear role in the treatment of poisoning
US6753341B1 (en) Inhibition of PKC to treat permability failure
Wrathall et al. Three case reports of the use of haemodiafiltration in the treatment of salicylate overdose
Schusser et al. Effect of hydroxyethyl starch solution in normal horses and horses with colic or acute colitis
US20250032435A1 (en) Dialysis concentrate
Kielstein et al. One for all–a multi-use dialysis system for effective treatment of severe thallium intoxication
Rittler et al. Use of the molecular adsorbent recycling system in the treatment of postoperative hepatic failure and septic multiple organ dysfunction–preliminary results
Grant et al. Rescue therapy for hypercapnia due to high PEEP mechanical ventilation in patients with ARDS and renal failure
Peltonen et al. The effect of combining intermittent hemodiafiltration with forced alkaline diuresis on plasma myoglobin in rhabdomyolysis
Jain et al. Pyrazinamide induced thrombocytopenia
Scott et al. Baclofen intoxication in a dog successfully treated with hemodialysis and hemoperfusion coupled with intensive supportive care
Biancofiore et al. Combined twice-daily plasma exchange and continuous veno-venous hemodiafiltration for bridging severe acute liver failure
WO2000053013A1 (en) Inhibition of pkc to treat permeability failure

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION